logo
Plus   Neg
Share
Email

Stock Watch: Agios Pharma Rises On Positive Cholangiocarcinoma Trial Data

Shares of Agios Pharmaceuticals Inc. (AGIO) rose more than 18% in extended trading on Wednesday, following positive results from its global phase III trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation.

Cholangiocarcinoma is a group of cancers that begin in the bile ducts. (Source: NIH). Advanced cholangiocarcinoma is a life-threatening disease with no currently approved treatment options.

In the phase III trial, dubbed ClarIDHy, treatment with TIBSOVO demonstrated a statistically significant improvement in progression-free survival compared with patients who received placebo.

TIBSOVO was approved by the FDA for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation last July. The drug generated $13.84 million of net product revenue from U.S. sales of TIBSOVO in 2018.

The Company plans to submit a supplemental new drug application for TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.

AGIO closed Wednesday's trading at $47.35, down 1.00%. In after-hours, the stock was up 18.80% to $56.25.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20... NetApp Inc. (NTAP) Wednesday reported a fourth-quarter profit that fell short of Wall Street estimates, as revenues slipped 3 percent. Shares of the company slipped 6% in extended trading session after its first-quarter outlook was also short of current expectations. Sunnyvale, California-based NetApp...
Follow RTT